Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
26 August 2022Website:
http://www.paxmedica.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
regular market | Thu, 21 Nov 2024 20:59:49 GMTDividend
Analysts recommendations
Institutional Ownership
PXMD Latest News
PaxMedica (NASDAQ: PXMD) has jumped 92.7% on Friday following the company's announcement of significant advancements in its drug development program, which has been well-received by the market.
PaxMedica stock is surging on Friday following the achievement of a significant milestone in drug development, with the company successfully obtaining three crucial batches of PAX-101.
PaxMedica (NASDAQ: PXMD ) stock is cratering today after the company announced a $7 million public offering. The offering consists of 5.38 million shares and warrants to purchase up to 5.38 million shares.
PaxMedica (NASDAQ: PXMD ) stock is jumping significantly higher against the backdrop of another soft session on Wall Street. This morning, management announced a productive discussion with the U.S. Food and Drug Administration (FDA) over positive clinical trial results for a key drug.
Clinical-stage biopharmaceutical firm PaxMedica (NASDAQ: PXMD ) is experiencing a full range of emotions following an initial spike in the market today. Earlier this morning, the company announced encouraging top-line results from its Phase 3 trial of PAX-101 (intravenous suramin), which met its primary endpoint.
What type of business is PaxMedica Common Stock?
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, fragile X syndrome, human African trypanosomiasis (HAT), and fragile X-associated tremor/ataxia syndrome. The company is developing PAX-102, an intranasal formulation of suramin for neurologic indications, as well as other new chemical entities that are targeted and selective antagonists of purine receptor subtypes; and PAX-HAT-301 for the treatment of HAT. It has a research collaboration agreement with PolarMar Health for Phase II clinical trial in austism spectrum disorder for emodin, which retains the rights for PolarMar to develop and commercialize any non-prescription supplement form of the product, and for PaxMedica, Inc. to retain exclusive rights to develop and commercialize a highly purified form of emodin. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York.
What sector is PaxMedica Common Stock in?
PaxMedica Common Stock is in the Healthcare sector
What industry is PaxMedica Common Stock in?
PaxMedica Common Stock is in the Biotechnology industry
What country is PaxMedica Common Stock from?
PaxMedica Common Stock is headquartered in United States
When did PaxMedica Common Stock go public?
PaxMedica Common Stock initial public offering (IPO) was on 26 August 2022
What is PaxMedica Common Stock website?
https://www.paxmedica.com
Is PaxMedica Common Stock in the S&P 500?
No, PaxMedica Common Stock is not included in the S&P 500 index
Is PaxMedica Common Stock in the NASDAQ 100?
No, PaxMedica Common Stock is not included in the NASDAQ 100 index
Is PaxMedica Common Stock in the Dow Jones?
No, PaxMedica Common Stock is not included in the Dow Jones index
When was PaxMedica Common Stock the previous earnings report?
No data
When does PaxMedica Common Stock earnings report?
Next earnings report date is not announced yet